A PMHNP is considering ordering whole-exome sequencing for a 25-year-old patient with early-onset schizophrenia to identify potential genetic variants contributing to his condition. The patient's mother, who accompanies him, is eager for the test, hoping it will 'explain what happened.' The patient has capacity and agrees to the testing. The PMHNP considers the unique informed consent requirements for psychiatric genetic testing that go beyond standard pharmacogenomic panels.